Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- GSK, Kyowa Kirin Join Hands for HIF-PH Inhibitor Daprodustat
November 26, 2018
- Astellas Grabs License to Gene Therapy JVS-100, with Acquisition also in Cards
November 26, 2018
- Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Earns FDA’s Priority Review Status
November 26, 2018
- Dissident Takeda Shareholders Making Final Pitch to Thwart Shire Buyout
November 26, 2018
- MHLW Approves Label Expansions for Praluent, Tremfya
November 22, 2018
- Mundipharma Obtains Exclusive Rights in Japan from South Korean Firm for Osteoarthritis Cell Therapy
November 22, 2018
- Takeda Voluntary Recalls 7 Narcotic Injectable Products after Confirming Coloring
November 22, 2018
- Takeda Gets European OK for Shire Deal with Strings Attached
November 21, 2018
- Pfizer’s ALK Inhibitor Lorbrena, Shire’s HAE Drug Now Available in Japan
November 21, 2018
- AbbVie Seeks Japan Approval for BCL-2 Inhibitor Venetoclax in CLL
November 21, 2018
- Takeda to Issue US$5.5 Billion in Bonds for Shire Acquisition
November 21, 2018
- Mitsubishi Tanabe Cuts FY2020 Targets in 5-Year Biz Plan on Flagging Royalty, Development Delay
November 21, 2018
- Sawai to Attach More Weight to Profits, Received Several Approaches for Possible Tie-Up: Chief
November 20, 2018
- Amgen Astellas’ Migraine Drug Hits Primary Endpoint in Japan PII
November 20, 2018
- 3 Japan Generic Majors Log 6% Growth in Combined April-September Sales despite Price Revision
November 20, 2018
- Fuji Pharma to Bolster Biosimilar Business as New Core
November 20, 2018
- High Court Upholds Not-Guilty Ruling for Novartis, Ex-Employee in Diovan Case
November 20, 2018
- Toray to Develop Small Molecule Cancer Drug Licensed from US Bioventure
November 20, 2018
- Chugai Sues Alexion in US over Soliris Successor ALXN1210
November 19, 2018
- 4 Major Wholesalers See 46.1% Increase in 1st Half Operating Profit due to Reductions in Yakkasa and SGA Costs
November 19, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…